Product
PT217
Name
PT217
1 clinical trial
4 indications
Indication
Small Cell Lung CancerIndication
Large Cell Neuroendocrine CancerIndication
Neuroendocrine Prostate CancerClinical trial
A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3.Status: Recruiting, Estimated PCD: 2025-01-01